RAP (ASX) A new Beginning...

Originally posted by CltestEdin ↑

Have been following Resapp for a while, through the recent ups and downs. Up to now i just read what other people posted and much appreciated all the different views offered...and thought might be good to throw in a couple different perspectives to get the chats going. Hope RAP will get some momentum soon as like some others you start to ask yourself if it's the right investment or not.

what's encouraging from RAP's LinkedIn profiles is that most engineers are very senior with lots of work experience, unlike other young startups where you see many graduates or junior engineers. I'd see this positive as most of them have been staying with RAP through the troughs so i'd assume they are still positive about the company's prospect. What's bewildering is that Prof.Abeyratne, Chief Scientist of RAP, starts in his profile "I will be seriously considering challenging new career advancement opportunities in 2018-2019", which to me feels like his mission is completed with RAP and want to pasture new. Given all the ongoing trials, he and his team should have much data to analyse and improve the algorithms. Anybody knows what does that mean?

Expand

Recent News

January 2019: Snore sound based Sleep Apnea diagnostics intellectual property developed by Dr. Udantha Abeyratne and his team are available for commercialisation. The technology is the culmination of 20 years of ground breaking work leading to four patent applications including two granted ones in the USA (the rest are under examination at various stages) and a large portfolio of peer reviewed publications in international scholarly journals. A Matlab implementation of technology and performance comparions against American Academy of Sleep Medicine scoring critera of 2007 (AASM 2007) are available. Prior comparisons on Chicago Criteria ("AASM 1999") are also available via peer-reviewed literature. Our software models indicate that the technology can diagnose sleep apnea at a sensitivity and specificity approching that of a standard facility-based polysomnography (sensitivity, specificity around 90%, 90%-- cross validation studies). Note that the model development data sets available to us had been scored per AASM 2007 clinical criteria. Thus, the resulting models require a straight-forward re-training (re-calibration) process on AASM 2012 data before they can be used on subjects diagnosed under AASM 2012 criteria (which is the clinical scoring standard in effect since 2012